A Phase II Study of UCN-01 in Metastatic Melanoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00072189
First received: November 4, 2003
Last updated: October 7, 2013
Last verified: October 2013

November 4, 2003
October 7, 2013
November 2003
March 2010   (final data collection date for primary outcome measure)
Response rate [ Time Frame: Up to 7 years ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00072189 on ClinicalTrials.gov Archive Site
  • Overall survival [ Time Frame: Up to 7 years ] [ Designated as safety issue: No ]
  • Progression-free survival [ Time Frame: From the date of study registration to the first documentation of progressive tumor, assessed up to 7 years ] [ Designated as safety issue: No ]
  • Toxicity measured using National Cancer Institute (NCI) Common Toxicity Criteria CTC) version 2.0 [ Time Frame: Up to 7 years ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
 
A Phase II Study of UCN-01 in Metastatic Melanoma
A Phase II Study of UCN-01 in Metastatic Melanoma

UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. This phase II trial is studying how well UCN-01 works in treating patients with metastatic melanoma.

PRIMARY OBJECTIVES:

I. To assess the anti-tumor activity of UCN-01 (7-hydroxystaurosporine) in metastatic melanoma, as determined by the response rate.

II. To assess the clinical and laboratory toxicities of UCN-01. III. To study the effects of UCN-01 administration on potential markers of specific G1-phase cell cycle regulators.

OUTLINE: This is a multicenter study.

Patients receive UCN-01 IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Patients are followed for survival.

PROJECTED ACCRUAL: A total of 17-33 patients will be accrued for this study within 18 months.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Recurrent Melanoma
  • Stage IV Melanoma
  • Drug: 7-hydroxystaurosporine
    Given IV
  • Other: laboratory biomarker analysis
    Correlative studies
  • Other: pharmacological study
    Correlative studies
Experimental: Treatment (7-hydroxystaurosporine)
Patients receive UCN-01 IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Interventions:
  • Drug: 7-hydroxystaurosporine
  • Other: laboratory biomarker analysis
  • Other: pharmacological study
Li T, Christensen SD, Frankel PH, Margolin KA, Agarwala SS, Luu T, Mack PC, Lara PN Jr, Gandara DR. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. Invest New Drugs. 2012 Apr;30(2):741-8. Epub 2010 Oct 22.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
33
Not Provided
March 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients have histologically or cytologically confirmed melanoma that is incurable by other means such as surgery, radiotherapy, or limb perfusion
  • Patients must have measurable disease, defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 10 mm with conventional techniques or with spiral CT scan, and which has clearly progressed during the observation interval prior to participation in this study
  • Patients must have received =< 1 prior chemotherapy and/or =< biological therapies; isolated limb perfusion with a biological and/or chemotherapeutic agent is allowed if the measurable disease and the lesion that will be biopsied for this protocol are outside the area of prior perfusion; at least 4 weeks must have elapsed since prior therapy (6 weeks for nitrosoureas or mitomycin C) and the patient must have recovered from all toxicities attributable to prior therapy
  • Life expectancy greater than 4 months
  • Eastern Cooperative Oncology Group (ECOG) performance status #2 (Karnofsky >= 60%)
  • Leukocytes >= 3000/uL
  • Absolute neutrophil count >= 1500/uL
  • Platelets >= 100000/uL
  • Total bilirubin =< 1.5 mg/dL
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 X institutional upper limit of normal
  • Creatinine < 1.6 mg/dL
  • Creatinine clearance >= 50 mL/min for patients with creatinine levels above 1.6 mg/dL
  • The effects of UCN-01 on the developing human fetus at the recommended therapeutic dose are unknown; for this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
  • Ability to understand and willingness to sign a written informed consent document
  • Patient must have a central venous catheter
  • Patients are requested to submit archival tissue for pre-study and undergo a tumor biopsy 24 hours post UCN-01 administration if feasible

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or who have not recovered from adverse events to agents administered more than 4 weeks earlier
  • Patients must not be receiving any other investigational agents
  • Patients with known brain metastases are eligible only if disease is controlled and patient is asymptomatic (i.e. at least 4 weeks from completion of whole brain irradiation, stereotactic radiosurgery, or gamma knife irradiation) and not receiving corticosteroids
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to UCN-01
  • Patients with only non-measurable disease, defined as all other lesions, including small lesions (longest diameter >= 10 mm with conventional techniques or with spiral CT scan) and truly non-measurable lesions, which include the following:

    • Bone lesions
    • Leptomeningeal disease
    • Ascites
    • Pleural or pericardial effusion
    • Abdominal masses that are not confirmed and followed by imaging techniques
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, systematic congestive heart failure, symptomatic pulmonary diseases, unstable angina pectoris, cardiac arrhythmia, prior mediastinal radiation or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because UCN-01 is a serine-threonine kinase inhibitor with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse effects in nursing infants secondary to treatment of the mother with UCN-01, breastfeeding should be discontinued if the mother is treated with UCN-01
  • Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with UCN-01; appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated
  • Due to the incidence of hyperglycemia with UCN-01, patients with a history of diabetes will be excluded from the study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00072189
NCI-2012-02829, NCI-2012-02829, PHII-33, 5536, N01CM17101
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Scott Christensen Beckman Research Institute
National Cancer Institute (NCI)
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP